Saturday, May 04, 2024 3:46:54 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent ORIC News
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/03/2026 08:30:00 PM
- ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC • GlobeNewswire Inc. • 03/27/2026 12:30:00 PM
- ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting • GlobeNewswire Inc. • 03/17/2026 09:01:24 PM
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/06/2026 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 10:06:19 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/23/2026 10:02:58 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/23/2026 09:58:55 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/23/2026 09:15:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:10:25 PM
- ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates • GlobeNewswire Inc. • 02/23/2026 09:05:00 PM
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/06/2026 09:30:00 PM
- ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/05/2026 09:01:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 01/21/2026 05:30:30 PM
- Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff • PR Newswire (Canada) • 01/14/2026 03:52:00 PM
- Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff • PR Newswire (US) • 01/14/2026 03:52:00 PM
- ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones • GlobeNewswire Inc. • 01/12/2026 01:30:00 PM
- ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2025 11:02:30 AM
- ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025 • GlobeNewswire Inc. • 12/06/2025 01:00:00 AM
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/05/2025 09:30:00 PM
- ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025 • GlobeNewswire Inc. • 12/05/2025 06:00:00 AM
- ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025 • GlobeNewswire Inc. • 12/05/2025 02:45:00 AM
- ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025 • GlobeNewswire Inc. • 12/03/2025 09:01:00 PM
- ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025 • GlobeNewswire Inc. • 12/01/2025 01:00:00 PM

